DYNE THERAPEUTICS INC (DYN) Stock Analyst Earnings Estimates
NASDAQ:DYN - Nasdaq - US26818M1080 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 11,555.98% | N/A 207.75% | N/A 108.31% | N/A 52.96% | N/A 36.47% | N/A 19.33% | ||||||||
| EBITDA YoY % growth | -4.78M | -13.56M -183.68% | -57.95M -327.36% | -148.94M -157.01% | -169.28M -13.66% | -240.489M -42.07% | -342.213M -42.30% | N/A -9.99% | N/A -4.15% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.8M | -13.83M -188.13% | -58.65M -324.08% | -150.03M -155.81% | -170.96M -13.95% | -242.162M -41.65% | -343.886M -42.01% | N/A -24.45% | N/A -7.12% | N/A 14.71% | N/A 61.04% | N/A 256.98% | N/A 138.64% | N/A 67.14% | N/A 27.48% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.91 -15.59% | -3.24 -11.34% | -3.94 -21.60% | -3.35 14.97% | N/A -16.05% | N/A 0.46% | N/A 22.68% | N/A 30.63% | N/A 130.17% | N/A 375.40% | N/A 76.51% | N/A 33.40% |
All data in USD
| Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.95 -17.03% | -0.98 -39.34% | -0.99 -2.65% | -1.01 -14.77% | -0.93 1.98% | -0.93 4.73% | -0.93 5.71% | -0.91 10.00% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -104.768M -51.49% | -108.998M -51.47% | -113.183M -7.12% | -119.87M -23.44% | -108.63M -3.69% | -108.868M 0.12% | -109.106M 3.60% | -109.348M 8.78% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2024 Q2Q % growth | -0.88 19.27% | -0.97 | 0.09 | 9.33% |
| Q3 2024 Q2Q % growth | -0.96 3.03% | -0.72 | -0.24 | -33.50% |
| Q2 2024 Q2Q % growth | -0.70 35.19% | -0.73 | 0.03 | 3.47% |
| Q1 2024 Q2Q % growth | -0.81 -3.85% | -0.81 | 0.00 | -0.25% |
| Q4 2023 Q2Q % growth | -1.09 -47.30% | -0.93 | -0.16 | -17.73% |
| Q3 2023 Q2Q % growth | -0.99 -23.75% | -0.84 | -0.15 | -17.74% |
| Q2 2023 Q2Q % growth | -1.08 -6.93% | -0.82 | -0.26 | -32.42% |
| Q1 2023 Q2Q % growth | -0.78 -13.04% | -0.78 | 0.00 | -0.46% |
| Q4 2022 Q2Q % growth | -0.74 26.00% | -0.85 | 0.11 | 13.29% |
| Q3 2022 Q2Q % growth | -0.80 3.61% | -0.93 | 0.13 | 14.06% |
| Q2 2022 Q2Q % growth | -1.01 -74.14% | -0.78 | -0.23 | -29.03% |
| Q1 2022 Q2Q % growth | -0.69 -38.00% | -0.89 | 0.20 | 22.59% |
| Q4 2021 Q2Q % growth | -1.00 -56.25% | -1.00 | 0.00 | -0.01% |
| Q3 2021 Q2Q % growth | -0.83 58.71% | -0.65 | -0.18 | -27.41% |
| Q2 2021 Q2Q % growth | -0.58 | -0.55 | -0.03 | -5.37% |
| Q1 2021 Q2Q % growth | -0.50 | -0.61 | 0.11 | 17.77% |
| Q4 2020 Q2Q % growth | -0.64 | -0.38 | -0.26 | -70.34% |
| Q3 2020 Q2Q % growth | -2.01 | -0.88 | -1.13 | -127.44% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -0.92% | 0% | -0.06% |
| Revenue | N/A | N/A | N/A | -100% |